Using and understanding medical statistics: 5th, revised and extended edition

Using and Understanding Medical Statistics: 5th, Revised and Extended Edition

Volumn , Issue , 2015, Pages 1-339

  Matthews, David Edward ^a   Farewell, Vernon Todd ^b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84946712924     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (93)

1. R Core Team: R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2015. http://www. R-project. org/.
2. Thomas PRM, Tefft M, D'Angio GJ, Norkool P, Farewell VT: Relapse patterns in irradiated Second National Wilms' Tumor Study (NWTS-2) patients. Proc Am Soc Clin Oncol 1983; 24: 69.
3. MRC Streptomycin in Tuberculosis Trials Committee: Streptomycin treatment of pulmonary tuberculosis. BMJ 1948;ii:769-783.
4. Backhouse CI, Matthews JA: Single-dose enoxacin compared with 3-day treatment for urinary tract infection. Antimicrob Agents Chemother 1989; 33: 877-880.
5. Storb R, Prentice RL, Thomas ED: Marrow transplantation for treatment of aplastic anemia. N Engl J Med 1977; 296: 61-66.
6. Medical Research Council: Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. BMJ 1950;ii:1073-1085.
7. Mantle MJ, Greenwood RM, Currey HLF: Backache in pregnancy. Rheumatol Rehabil 1977; 16: 95-101.
8. Bishop YMM: Full contingency tables, logits, and split contingency tables. Biometrics 1969; 25: 383-399.
9. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
10. Berkson J, Gage RP: Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin 1950; 25: 270-286.
11. Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8: 699-712.
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. James RC, Matthews DE: The donation cycle: a framework for the measurement and analysis of blood donor return behaviour. Vox Sang 1993; 64: 37-42.
14. James RC, Matthews DE: Analysis of blood donor return behaviour using survival regression methods. Transfus Med 1996; 6: 21-30.
15. Follmann DA, Goldberg MS, May L: Personal characteristics, unemployment insurance, and the duration of unemployment. J Econom 1990; 45: 351-366.
16. Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, Law M, Bateman M, Klatt NE, Dose AM, Etzell PS, Nelimark RA, Mailliard JA, Moertel CG: Prospective evaluation of prognostic variables from patient-completed questionnaires. J Clin Oncol 1994; 12: 601-607.
17. Matthews D: Exact nonparametric confidence bands for the survivor function. Int J Biostat 2013; 9: 185-204.
18. Prentice RL, Marek P: A qualitative discrepancy between censored data rank tests. Biometrics 1979; 35: 861-867.
19. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203-223.
20. Peto R, Peto J: Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 1972; 135: 185-206.
21. Pearson K, Lee A: On the laws of inheritance in man. I. Inheritance of physical characters. Biometrika 1903; 2: 357-462.
22. Wainwright P, Pelkman C, Wahlsten D: The quantitative relationship between nutritional effects on preweaning growth and behavioral development in mice. Dev Psychobiol 1989; 22: 183-195.
23. Armitage P, Berry G, Matthews JNS: Statistical Methods in Medical Research, ed 4. Oxford, Blackwell Science, 2002.
24. Duncan BBA, Zaimi F, Newman GB, Jenkins JG, Aveling W: Effect of premedication on the induction dose of thiopentone in children. Anaesthesia 1984; 39: 426-428.
25. von Bortkiewicz L: Das Gesetz der kleinen Zahlen. Leipzig, Teubner, 1898.
26. Fallowfield L, Jenkins V, Farewell V, Saul J, Duffy A, Eves R: Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial. Lancet 2002; 359: 650-656.
27. Breslow NE, Day NE: Statistical Methods in Cancer Research, vol II: The Design and Analysis of Cohort Studies. Lyon, International Agency for Research in Cancer, 1987.
28. Trinchieri G, Kobayashi M, Rosen M, Loudon R, Murphy M, Perussia B: Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med 1986; 164: 1206-1225.
29. van den Broek J: A score test for zero inflation in a Poisson model. Biometrics 1995; 51: 738-743.
30. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
31. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE: The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554.
32. Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Vasudevan A, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Steinsson K, Khamashta M, Alarcón GS, Fessler B, Petri M, Manzi S, Nived O, Sturfelt G, Ramsey-Goldman R, Dooley MA, Aranow C, Van Vollenhoven R, Ramos-Casals M, Zoma A, Kalunian K, Farewell V; Systemic Lupus International Collaborating Clinics (SLICC): SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 961-967.
33. Liang K-Y, Zeger S: Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
34. Zeger SL, Liang K-Y: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121- 130.
35. Gladman DD, Farewell VT, Nadeau C: Clinical indicators of progression in psoriatic arthritis (PSA): a multivariate relative risk model. J Rheumatol 1995; 22: 675-679.
36. Kalbfleisch JD, Lawless JF: The analysis of panel data under a Markov assumption. J Am Stat Assoc 1985; 80: 863-871.
37. Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD: Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum 2005; 53: 404-409.
38. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982; 1: 121-129.
39. Pocock SJ: Clinical Trials, a Practical Approach. Chichester, Wiley, 1983.
40. Piantadosi S: Clinical Trials: A Methodologic Perspective, ed 2. Hoboken, Wiley, 2005.
41. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
42. Cox DR: Planning of Experiments. New York, Wiley, 1958.
43. Breslow N: Perspectives on the statistician's role in cooperative clinical research. Cancer 1978; 41: 326-332.
44. Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, De Mets DL, Ellenberg JH, Gail MH, Ware JH: Randomized clinical trials. N Engl J Med 1976; 295: 74-80.
45. Chalmers TC: Randomized clinical trials in surgery; in Varco RL, Delaney JP (eds): Controversy in Surgery. Philadelphia, Saunders, 1976, pp 3-11.
46. Chalmers TC, Block JB, Lee S: Controlled studies in clinical cancer research. N Engl J Med 1972; 287: 75-78.
47. Cox DR: Summary views: a statistician's perspective. Cancer Treat Rep 1980; 64: 533-535.
48. Farewell VT, D'Angio GJ: A simulated study of historical controls using real data. Biometrics 1981; 37: 169-176.
49. Freireich EJ: The randomized clinical trial as an obstacle to clinical research; in Delaney JP, Varco RL (eds): Controversies in Surgery. II. Philadelphia, Saunders, 1983, pp 5-12.
50. Gehan EA, Freireich EJ: Non-randomized controls in cancer clinical trials. N Engl J Med 1974; 290: 198-203.
51. Sacks H, Chalmers TC, Smith H: Randomized versus historical controls for clinical trials. Am J Med 1982; 72: 233-240.
52. Pocock SJ, Elbourne DR: Randomized trials or observational tribulations. N Engl J Med 2000; 342: 1907-1909.
53. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG. Evaluating nonrandomised intervention studies. Health Technol Assess 2003; 7:iii-x, 1-173.
54. Yule GU: The Function of Scientific Method in Scientific Investigation. Industrial Fatigue Research Board Report 28. London, HMSO, 1924.
55. Irwin JO: The place of mathematics in medical and biological statistics. J R Stat Soc A 1963; 126: 1-45.
56. Choy EHS, Smith CM, Farewell V, Walker D, Hassell A, Chau L, Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008; 67: 656-663.
57. McPherson K: Statistics: the problem of examining accumulating data more than once. New Engl J Med 1974; 290: 501-502.
58. Whitehead J: The Design and Analysis of Sequential Clinical Trials, ed 2. New York, Horwood, 1991.
59. Fleming TR, Harrrington DP, O'Brien PC: Designs for group sequential tests. Control Clin Trials 1984; 5: 348-361.
60. Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440.
61. Fleming TR: Evaluating therapeutic interventions: some issues and experiences. Stat Sci 1992; 7: 428-456.
62. Burzykowski T, Molenberghs G, Buyse M (eds): The Evaluation of Surrogate Endpoints. New York, Springer, 2005.
63. Fleming TR: Evaluation of active control trials in AIDS. J Acquir Immune Defic Syndr 1990; 3:S82-S87.
64. Cox DR: A remark on multiple comparison methods. Technometrics 1965; 7: 223-224.
65. Pocock SJ, Geller NL, Tsiatis AA: The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43: 487-498.
66. Torrance GW: Utility approach to measuring health related quality of life. J Chronic Dis 1987; 40: 593-600.
67. Cox DR, Fitzpatrick R, Fletcher AE, Gore SM, Spiegelhalter DJ, Jones DR: Quality of life assessment: can we keep it simple? J R Stat Soc A 1992; 155: 353-393.
68. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J: Adaptive designs in clinical drug development - an executive summary of the Ph RMA working group. J Biopharm Stat 2006; 16: 275-283.
69. Peto R, Collins R, Gray R: Large-scale randomized evidence: large, simple trials and overviews of trials; in Warren KS, Mosteller F (eds): Doing More Good Than Harm: The Evaluation of Health Care Interventions. Ann NY Acad Sci 1993; 703: 314-340.
70. Light RJ, Pillemer DB: Summing up. The Science of Reviewing Research. Cambridge, Harvard University Press, 1984.
71. Sterne JAC, Egger M: Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidem 2001; 54: 1046-1055.
72. Egger M, Davey Smith G: Misleading meta-analysis. Lessons from 'an effective, safe, simple' intervention that wasn't. BMJ 1995; 310: 752-754.
73. Lilienfeld AM, Lilienfeld DE: Foundations of Epidemiology, ed 3. New York, Oxford University Press, 1994.
74. Prentice RL, Shimizu Y, Lin CH, Peterson AV, Kato H, Mason MW, Szatrowski TP: Serial blood pressure measurements and cardiovascular disease in a Japanese cohort. Am J Epidemiol 1982; 116: 1-28.
75. Weiss NS, Szekeley DR, English DR, Schweid AJ: Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 1979; 242: 261-264.
76. Breslow NE, Day NE: Statistical Methods in Cancer Research, vol 1: The Analysis of Case-Control Studies. Lyon, International Agency for Research in Cancer, 1980.
77. Hauck WW: The large sample variance of the Mantel-Haenszel estimator of a common odds ratio. Biometrics 1979; 35: 817-819.
78. Robins J, Breslow N, Greenland S: Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986; 42: 311-323.
79. Doll R, Hill AB: Mortality of British doctors in relation to smoking: observations on coronary thrombosis. Natl Cancer Inst Monogr 1966; 19: 205-268.
80. McNeil D: Epidemiological Research Methods. New York, Wiley, 1996.
81. Weiss NS: Clinical Epidemiology: The Study of the Outcome of Illness, ed 2. New York, Oxford University Press, 1996.
82. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, de Kernion JB, Ratliff TL, Kavoussi LR, Dalkin BL: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152: 2037-2042.
83. Ransohoff DF, Feinstein AR: Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299: 926-930.
84. Reid MC, Lachs MS, Feinstein AR: Use of methodological standards in diagnostic test research: getting better but still not good. JAMA 1995; 274: 645-651.
85. Lusted LB: Introduction to Medical Decision Making. Springfield, Thomas, 1968.
86. Sackett DL, Haynes RB, Guyatt GH, Tugwell P: Clinical Epidemiology: A Basic Science for Clinical Medicine, ed 2. London, Little, Brown, 1991.
87. Fagan TJ: Nomogram for Bayes' theorem. N Engl J Med 1975; 293: 257-261.
88. Guyatt GH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C: Laboratory diagnosis of iron-deficiency anaemia: an overview. J Gen Intern Med 1992; 7: 145-153.
89. Peabody GW: The physician and the laboratory. Boston Med Surg J 1922; 187: 324-327.
90. De Vet H: Observer reliability and agreement; in Armitage P, Colton T (eds): Encyclopedia of Biostatistics, ed 2. Chichester, Wiley, 2005, pp 3801-3805.
91. Isenberg DA, Allen E, Farewell VT, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis D, Pilkinton C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004; 43: 49-54.
92. Allen EJ, Farewell VT: The use of variance components for the assessment of outcome measures in rheumatology. J Appl Stat 2011; 38: 145-159.
93. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 327: 307-310.